



## Biomarkers for Skin Cancer Patients

Guest Editor:

### **Prof. Dr. Thilo Gambichler**

1. Skin Cancer Center,  
Department of Dermatology,  
Ruhr-University Bochum,  
Bochum, Germany  
2. Department of Dermatology,  
Christian Hospital Unna, Unna,  
Germany

Deadline for manuscript  
submissions:

**closed (30 September 2022)**

### **Message from the Guest Editor**

Cancer biomarkers can be measured in blood, organ tissue, or bodily fluids, and are increasingly used to identify the presence of malignancy and help to determine its stage, subtype, and whether a patient will respond to treatment, experience recurrent disease, or even die from cancer. Today, biomarkers play a crucial role in the diagnosis, therapy, and management of patients suffering from skin malignancies. On the other hand, biomarkers are increasingly established to detect patients with more favorable prognosis who may safely waive over-treatment. Moreover, biomarkers may help to identify patients who are at lower risk and may therefore undergo a follow-up regimen that is less strict. However, there are still challenges in the development of novel noninvasive biomarkers with greater clinical performance. The present Special Issue particularly focusses on original research findings and reviews on skin cancer biomarkers, which may include (but are not limited to) genetic, genomic, epigenomic, proteomic, cellular, and morphologic factors predisposing to skin cancers, indicating the presence of skin cancer, or correlating with treatment response and disease outcome.

